Navigation Links
Cancer Treatment Centers of America(R) Studies Treatment That Aims Chemotherapy Directly at Ovarian Cancer Cells
Date:6/17/2009

Therapy targets folate receptors found on cancer cells otherwise resistant to standard chemo

ZION, Ill., June 17 /PRNewswire-USNewswire/ -- Cancer Treatment Centers of America (CTCA) at Midwestern Regional Medical Center, a leading provider of innovative cancer care for patients living with complex and advanced-stage disease, is the only hospital in Illinois and Wisconsin to take part in new clinical research involving a treatment designed to target ovarian cancer cells otherwise resistant to standard chemotherapy.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090612/CTCALOGO)

The Phase II clinical study, called "PRECEDENT," is designed to evaluate the safety and efficacy of EC145, a drug currently being studied in the treatment for women with ovarian cancer who develop a resistance to standard platinum-based chemotherapy. EC145 was developed by Endocyte, a privately-held biotechnology company.

"With EC145, we're working to target a powerful chemotherapy drug directly to cancer cells while sparing the healthy cells," says Dr. Sybilann Williams, MD, gynecologic oncologist and surgeon at Cancer Treatment Centers of America at Midwestern Regional Medical Center and principal investigator for the PRECEDENT study. "EC145 is designed to target the folate receptors found in high concentrations on cancer cells," she adds.

In order to be eligible for the PRECEDENT study, patients must have platinum-resistant ovarian cancer where the disease has progressed or recurred within six months of a first or second treatment with a platinum-based chemotherapy drug. Those elig
'/>"/>

SOURCE Cancer Treatment Centers of America
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. CuraGen Announces Expansion of CR011-vcMMAE Phase II Trial in Advanced Breast Cancer
2. Study Suggests Vitamin D Screening and Appropriate Supplementation Indicated for All Cancer Patients
3. Researchers Say More Aggressive Vitamin D Supplementation Needed in Obese Cancer Patients
4. Jennerex Therapeutic Research Collaboration With Ottawa Hospital Research Institute Selected for $10 Million Grant From Ontario Institute for Cancer Research
5. Heaviest Smokers Face Greatest Risk of Death After Lung Cancer Diagnosis
6. Advance in Bowel Cancer Test Research
7. Investigational Cancer Drug BSI-201 Showed Clinical Benefit in 62% of Patients with Triple-Negative Metastatic Breast Cancer and Significantly Prolonged Survival
8. Peregrine Pharmaceuticals Highlights Promising Early Data From Its Three Phase II Bavituximab Cancer Trials
9. Paclitaxel Poliglumex (OPAXIO(TM)) Added to Cisplatin and Radiation Produces 45% Pathologic Complete Remissions in Patients With Esophageal Cancer
10. Medivation Announces Positive New Efficacy Data From Phase 1-2 Trial of MDV3100 in Advanced Prostate Cancer Patients
11. Researchers at the Karmanos Cancer Institute in Detroit Discover Feasibility of Chemotherapy Alternative
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014  Novation, the leading health care supply ... new IT value-added reseller (VAR) national contracts that ... IT goods and services at lower costs. These ... as value-added services such as initiative assistance and ... Novation agreements were awarded to CDW Government, Paragon ...
(Date:1/15/2014)... 15, 2014  Humberto C. Antunes,  Galderma  worldwide CEO, ... the Journal of Drugs in Dermatology (JDD) ... (ODAC). The event is January 17-20, 2014, at the Omni Orlando ... The ODAC is a distinguished event ... dermatology for clinical and aesthetic dermatology practitioners in the ...
(Date:1/15/2014)... Jan. 15, 2014 Tegra Medical is very ... Mark King as its new Chief Executive Officer.  ... Operating Officer, in which he has overseen the company,s ... Mississippi , and Costa Rica.  Mr. King ... broad-based operations, sales, engineering and manufacturing experience in medical ...
Breaking Medicine Technology:New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3
... With 30 Installed Inveon Imaging Systems, Siemens ... Position in Preclinical Imaging Centers, HOFFMAN ... adage,says "a picture is worth 1,000 words," ... research where high-resolution images can validate years ...
... Results Seen Since Presentation ... to Include Alvespimycin Plus Trastuzumab Plus ... Paclitaxel Regimen, HAYWARD, ... data from a Phase 1 clinical,trial showing that alvespimycin, its second-generation Hsp90 ...
Cached Medicine Technology:Siemens Preclinical Imaging System Helps The Methodist Hospital in Houston Further Its Research Mission 2Siemens Preclinical Imaging System Helps The Methodist Hospital in Houston Further Its Research Mission 3Siemens Preclinical Imaging System Helps The Methodist Hospital in Houston Further Its Research Mission 4Siemens Preclinical Imaging System Helps The Methodist Hospital in Houston Further Its Research Mission 5Kosan's Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial 2Kosan's Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial 3Kosan's Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial 4Kosan's Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial 5
(Date:4/16/2014)... Celldex Therapeutics, Inc. (NASDAQ: CLDX) announced today that ... CDX-1401 in solid tumors, including long-term patient follow-up, ... (Vol 6 Issue 232). The data demonstrate ... of clinical benefit in patients with very advanced ... to better outcomes on subsequent therapy with checkpoint ...
(Date:4/16/2014)... According to a new study, endoscopists, recommendations for ... to two small polyps are consistent with guideline recommendations ... an appropriate target for quality indicators. This is the ... guidelines for timing of repeat colonoscopy after one to ... average-risk patients. The study appears in the April issue ...
(Date:4/15/2014)... diabetes and pre-diabetes in the United States have nearly ... Hopkins Bloomberg School of Public Health, with obesity apparently ... that the burden of the disease has not hit ... blacks, Hispanics and the elderly. , According to new ... the Annals of Internal Medicine , diabetes increased ...
(Date:4/15/2014)... decades-old medical mystery and in the process have found ... which kill about 1.5 million people a year. The researchers ... an antifungal drug that has been in use for more ... toxic to human cells as it is to the microbes ... findings appears in Nature Chemical Biology . , "Invasive ...
(Date:4/15/2014)... Diego School of Medicine have identified a mechanism that ... liver disease and why the virus is able to ... The hard-to-kill pathogen, which infects an estimated 200 million ... the mitochondria dismantling the cell,s innate ability to ... dynamics. , The study, published in today,s issue of ...
Breaking Medicine News(10 mins):Health News:Celldex's Phase 1 study of CDX-1401 published in Science Translational Medicine 2Health News:Celldex's Phase 1 study of CDX-1401 published in Science Translational Medicine 3Health News:Celldex's Phase 1 study of CDX-1401 published in Science Translational Medicine 4Health News:Surveillance colonoscopy recommendations for average-risk patients with 1 to 2 small polyps consistent with guidelines 2Health News:Surveillance colonoscopy recommendations for average-risk patients with 1 to 2 small polyps consistent with guidelines 3Health News:Pre-diabetes and diabetes nearly double over the past 2 decades 2Health News:Potent, puzzling and (now less) toxic: Team discovers how antifungal drug works 2Health News:Potent, puzzling and (now less) toxic: Team discovers how antifungal drug works 3Health News:Breaking bad mitochondria 2
... CHAPEL HILL, N.C., Nov. 2 With ... the manufacturing environment, best-in-class,companies continue to focus ... internal and external customer relationships. In reviewing,the ... more,than three-quarters of the benchmark class posts ...
... 2 Addressing more than,100 cardiologists and other ... and CEO, set out four critical priorities for,improving ... at,Schering-Plough,s fourth annual Cardiovascular Summit in advance of ... In his speech, Hassan emphasized the potential for ...
... Hair to Help ... Women with Cancer, CINCINNATI, Nov. 2 Two-time Oscar winner,Hilary ... of support for women with cancer. This national campaign,encourages people to ... create free wigs for women who have lost their hair due ...
... Recent outbreaks of,antibiotic-resistant Staphylococcus aureus, more commonly known as ... healthy people,can carry on the skin or nose, it is ... the skin, in the blood, in the bones and,in the ... of antibiotics.,While most of these infections are minor, some however, ...
... Icon Supports Bargaining for Improved Patient Care, HUNTINGTON ... and co-founder of the United Farm Workers of,America, will ... Park for a walkthrough to shed light on patient ... year, caregivers have been seeking a new contract at,the ...
... Technique just as effective in patients under 60, study finds ... known as brachytherapy, are just as effective for treating prostate ... older men, a new study finds. , Brachytherapy is ... placed in the prostate to kill cancer cells. Recovery time ...
Cached Medicine News:Health News:Manufacturing Organizations Identify Efficiencies in Credit and Collections Functions 2Health News:Schering-Plough CEO Calls for Four-Pronged Approach to Improving Current Health Care Environment 2Health News:Hilary Swank Donates Her Hair to Pantene(R) Beautiful Lengths(TM) 2Health News:Hilary Swank Donates Her Hair to Pantene(R) Beautiful Lengths(TM) 3Health News:Hilary Swank Donates Her Hair to Pantene(R) Beautiful Lengths(TM) 4Health News:Radiation Seed Treatment Helps Younger Men Fight Prostate Cancer 2
... Freedom leg bags are part ... a versatile line of leg bags, ... the varied needs of our customers. ... several sizes, and constructed of 100% ...
... part of the Freedom Urinary Collection ... bags, kits, and accessories designed to ... customers. These leg bags are offered ... 100% latex-free soft, textured medical grade ...
... are part of the Freedom Urinary ... leg bags, kits, and accessories designed ... our customers. These leg bags are ... of 100% latex-free soft, textured medical ...
The latex-free, PVC-free Antibacterial Hydro Personal catheter combines two remarkable innovations into one exclusive catheter that delivers an antibacterial agent while providing the virtually frict...
Medicine Products: